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related to excessive mucus production, symptoms related 
excessive gas production gas and symptoms related excessive 
blood production. A modern scoring system should have two 
or more atomized symptoms related to each of the six 
illnesses and appropriate response scales for frequency, 
intensity and duration. 
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Anorectal toxicity is a relevant side effect of pelvic 
radiotherapy for rectal, anal, gynaecologic and prostate 
cancer. Toxicity can be scored objectively by the physician 
according to established systems such as the CTCAE 
classification. In recent years, patient-reported outcomes 
(PROs) have received increasing attention when evaluating 
acute toxicity as well as late effects of cancer treatment. 
These include information directly obtained from the patient 
on symptoms and impairment as well as on quality of life. 
This presentation will focus on validated instruments to 
measure PROs related to anorectal function, including 
quality-of-life questionnaires and organ modules, e. g. those 
developed by the EORTC Quality of Life Group, and symptom 
questionnaires e. g. to measure continence. Objective 
measurements to quantify anorectal function such as 
sphincter manometry and endoscopic scores will be 
reviewed. The relationship between PROs and objective 
function assessment with physician-rated toxicity will be 
addressed. The outcomes for the above endpoints in major 
trials of pelvic radiotherapy will be presented, with a focus 
on rectal cancer and the effects of treatment concepts 
including short-course radiotherapy and long-course 
chemoradiation. Finally, dose-volume constraints in pelvic 
radiotherapy treatment planning and potential effects of 
highly conformal techniques such as IMRT or VMAT on 
anorectal symptoms, function and quality of life will be 
examined. 
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Radiotherapy is a well recognozed curative treatment option 
for localized prostate cancer. Optimal tumor control rates 
can only be achieved with high local doses, associated with a 
considerable risk of rectal toxicity - regarded as dose-limiting 
toxicity. Apart from already widely adapted technical 
advances, as intensity-modulated radiation therapy and 
image-guided radiotherapy techniques, the application of 
spacers placed between the prostate and anterior rectal wall 
has been increasingly used in the last years.  
Biodegradable spacers, including hydrogel, hyaluronic acid, 
collagen or an implantable balloon can create the desired 
effect. They can be injected or inserted in a short procedure 
under transrectal ultrasound guidance via a transperineal 
approach. A distance of about 1.0-1.5cm is usually achieved 
between the prostate and rectum, excluding the rectal wall 
from the high isodoses. Several studies have shown well 
tolerated injection procedures and treatments. Apart from 
considerable reduction of rectal dose compared to 
radiotherapy without a spacer, clinical toxiciyt results are 
favourable. A prospective randomized trial demonstrated a 
reduction of rectal toxicity after hydrogel injection in men 
undergoing prostate image-guided intensity-modulated 
radiation therapy. The results are encouraging for continuing 
evaluation in dose escalation, hypofractionation, stereotactic 
radiotherapy or re-irradiation trials in the future. 
 
 
 
 
 
 
Symposium: Towards user oriented QA procedures for 
treatment verification  
 
 
SP-0021  
How to ensure the quality in brachytherapy treatment 
planning systems? 
F.A. Siebert
1University Hospital S-H Campus Kiel, Academic Physics, Kiel, 
Germany 
1 
 
Treatment planning systems (TPSs) are of high importance in 
modern brachytherapy. The users rely on the output of these 
special software; wrong calculations may result in severe 
patient harm. Thus it is necessary to systematically check 
these software programs. 
Many checks in TPSs are identical for high-dose-rate 
brachytherapy with afterloaders and low-dose-rate 
brachytherapy with seeds. But some differences exist, e.g. as 
checking of afterloader parameters.  
After the installation of the software the acceptance test is 
to be carried out. This test protocol is typically provided by 
the vendor and should be passed before further checking. In 
a second step the commissioning is carried out. In this 
procedure all clinical relevant data and properties of the TPS 
must be tested and reported. Examples for items to check 
are:  
- Afterloader characteristics (number of channels, min./max. 
channel lengths, max. allowed dwell time, …) 
- Source characteristics (nuclide, decay, …) 
- TG-43 consensus dataFor Model-based dose calculation 
algorithms, commissioning following TG-186 report 
- Applicator checks 
To ensure the consistency and data integrity of the TPS 
periodical tests should be performed after the 
commissioning. Important points are to validate the integrity 
of base parameters of the TG-43 data and the recalculation 
of patient treatment plans.  
Most TPSs offer inverse planning algorithms. The algorithm 
itself is often not fully transparent by the user, thus 
comparison with manual calculations is not practical. 
Nevertheless, the consistency of such planning technique can 
be checked by recalculation of a test plan using a constant 
parameter set. In addition to the tests above end-to-end 
tests can be performed to check the whole treatment chain, 
including imaging, TPS, afterloader, and data transfer. 
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In the past decade 3D image guided brachytherapy has been 
introduced into clinical practice worldwide. This enables 
conformation of the dose distribution to the target volume 
and avoidance of high dose to organs at risk (OAR) using CT, 
MR, and/or ultrasound (US) imaging. In such modern 
techniques sectional images give the relationship of the 
shape and the position of the applicator(s)/sources in 
relation to the anatomy of the patients. This means that the 
quality assurance (QA) programs also should include specific 
topics related to image quality additional to traditional 
procedures checking the source strengths and dose 
calculation issues. QA for image quality is well established in 
the area diagnostic and many of these procedures can be 
used also for brachytherapy. However, the procedures should 
be modified in order to reflect the conditions of use in 
brachytherapy compared to a diagnostic session.  
To optimise the image quality in diagnostic procedures 
dedicated phantom is often used. Various image quality 
parameters are tested by evaluation for example slice 
thickness, spatial resolution, uniformity and noise. In 
contrast to diagnostic imaging, the ability to reconstruct 
several points or a geometric structure with high accuracy is 
crucial in brachytherapy. Therefore, a procedure to check 
the geometric accuracy have to be included in a QA program. 
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A phantom with known geometry should be used, either 
including markers with known relative coordinates or test 
objects with known shapes and volumes. The design of the 
phantom will be depend of the modality to be tested.  
For ultrasound imaging the AAPM Task Group 128 includes a 
list with 8 elements of a phantom that allow for all the 
recommended tests [1]. It is referred to a commercial 
phantom that include nylon monofilaments in a N-shaped 
pattern and spherical and non-spherical volume in order to 
test key imaging parameters such as depth of penetration, 
axial and lateral resolution, distance, area and volume 
measurements and geometric consistency.  
Roué et al used a commercial PMMA phantom with 25 
stainless steel markers with known relative position to check 
the geometric accuracy of CT and conventional x-ray imaging 
[2]. A phantom including several inserts with different 
density can be used to check the volume reconstruction 
accuracy for CT. Several commercial phantoms are available.  
It is well known that geometrical distortions can frequently 
occur in MR images. The magnitude of the distortions should 
be investigated by using phantoms with markers or tubes 
filled with for example Cu2+-doped water solution. 
Additional, the influence of an applicator should also be 
investigated since for example the presence of a titanium 
applicator may produce geometric distortion in a high field 
MR machine.  
The slice thickness will also influence the ability to 
reconstruct the geometry correctly. With too large distance 
between the slices the partial volume effect will influence 
the accuracy of the volume reconstruction [3]. On the other 
hand, de Brabandere et al showed that too small distance 
between the slices decreased the accuracy of seed detection 
in a dedicated phantom with agarose gel and 60 iodine seeds 
with known position using MR imaging [4].  
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Any radiotherapy delivery is associated with uncertainties 
and with risk of misadministration/error. 
Misadministration/error refers to treatment 
incidents/accidents which can be prevented, while 
uncertainties can only be controlled to a certain degree and 
the residual variation must be accounted for through 
tolerances and treatment margins. Patient safety through 
prevention of radiation dose misadministration is highly 
prioritised and several authorities and societies worldwide 
are focusing on radiation safety and medical events. In 2004, 
the International Commission of Radiation Protection (ICRP) 
reported an analysis of 500 radiation events in BT. This 
investigation and others have shown that a significant share 
of radiation events are caused by human errors related to the 
manual procedures of BT. Verification in radiation therapy 
means the whole process of proof that planned dose is 
delivered to the patient within a specific level of accuracy. 
During the last two decades enormous developments and 
technological innovations in the field of external beam 
radiotherapy (EBRT) treatment verification have taken place. 
These developments have focussed on imaging technologies 
for 2D and 3D (and very actually also 4D) localization and 
anatomy reconstruction under treatment delivery conditions. 
Striking innovations have been imaging technologies such as 
flat panel detectors, cone beam CT (CBCT), and most 
recently MRI, which is integrated with the linear 
accelerators. The combination of 3D-imaging techniques and 
dose measurements enables the estimation of the daily 3D-
dose delivery in the patient anatomy. In contrast, on-board 
or real-time treatment verification of BT is currently not 
performed, simply because adequate tools are not available. 
There is currently a striking unbalance between the 
availability of treatment verification technology for EBRT and 
BT, and consequently a different level of safety. Adding even 
further to this unbalance, BT is related with higher risk of 
major dose misadministration than EBRT, since BT involves: 
1) more manual procedures (e.g. assembly and implantation 
of applicators, catheter reconstruction, and guide tube 
connection), 2) mechanical equipment with a higher 
susceptibility to malfunction (e.g. source cable drive and 
applicators), 3) more frequent application of hypo-
fractionation schedules, and finally 4) steeper dose 
gradients. New methodologies for treatment verification are 
highly warranted. Dose and source geometry are closely 
linked entities in brachytherapy. Dose calculation with TG43 
is the current standard of dose calculation in brachytherapy, 
and has excellent accuracy in most clinical scenarios. TG43 is 
based on geometry. Given a direct correspondence between 
brachytherapy source geometry and dose, a geometric 
verification is nearly equivalent to a dosimetric verification. 
There are only few error scenarios where source geometry 
would be correct, but not dosimetry – e.g. source mis-
calibration. Therefore several novel “on-board” treatment 
verification tools are focused on verification of geometry: EM 
tracking of catheters, flat panel monitoring of source 
progression, fluoroscopy, and real-time in vivo dosimetry. 
Given the source geometry is correct, the next important 
step is to secure that the relation between sources and 
anatomy is correct. This last step is typically explored with 
imaging. Combinations between different verification tools 
may be the way to proceed to reach a higher level of 
treatment verification in brachytherapy which address 
geometry, patient anatomy and consequent dose delivery to 
the patient. The presentation will outline current 
developments in “on-board” treatment verification tools. The 
table below shows the current status of treatment 
verification in EBRT and BT, and indicates visions that can 
bring brachytherapy treatment verification forward. 
 
Symposium: Robust and accurate functional MRI for 
radiotherapy  
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Anatomical imaging with T1 and T2-weighted MRI is 
increasingly used in combination with CT for precise 
delineation of tumors and normal structures. MRI also offers 
functional techniques, such as diffusion-weighted MRI (DWI) 
and dynamic contrast-enhanced MRI (DCE-MRI). These can be 
applied in radiotherapy for tissue classification, monitoring of 
treatment response as well as for dose painting. In the 
diagnostic setting, these sequences are often part of routine 
scanning protocols. However, as for anatomical MRI 
sequences, there are some specific issues that need to be 
considered when applying these techniques in radiotherapy. 
For image registration with the planning CT, patients need to 
be scanned in treatment position. If the functional images 
are used for target delineation, their geometrical fidelity 
needs to be verified. In particular diffusion-weighted MRI is 
prone to geometrical distortions. Methods to reduce these 
distortions will be discussed. The spatial resolution of 
functional imaging tends to be lower than that of anatomical 
imaging. Although acquisition with small imaging voxels is 
feasible, this doesn’t mean that the functional quantity 
(apparent diffusion coefficient for DWI and tracer kinetics 
parameters for DCE-MRI) can be reliably determined in a 
